Other Information.
+Added: In November 2021, we were alerted to falsified information circulating on social media relating to our planned poster presentation for the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250 at the San Antonio Breast Cancer Symposium.
+Added: The falsified poster image was not released or authorized by us.
+Added: In December 2021, a Special Committee of our Board of Directors, with assistance of outside counsel, initiated an investigation into the circumstances regarding these matters.
+Added: The Special Committee’s outside counsel contacted the SEC to inform of the Special Committee’s investigation.
Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).
2 unchanged sentences
Amended and Restated Bylaws
+Added: Olema Pharmaceuticals, Inc.
+Added: 2022 Inducement Plan
+Added: Form of Stock Option Agreement and Option Grant Notice under the Inducement Plan.
+Added: Offer Letter by and between the Registrant and Naseem Zojwalla, dated December 15, 2021.
Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
Olema Pharmaceuticals, Inc.
−Removed: November 10, 2021
/s/ Sean Bohen, M.D., Ph.D.
3 unchanged sentences
Olema Pharmaceuticals, Inc.
−Removed: November 10, 2021
/s/ Shane Kovacs
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.